publication . Article . 2021

The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic

Babak Valeriya; Tatiana Beketova; Marina Suprun;
Open Access
  • Published: 03 Mar 2021 Journal: Rheumatology Science and Practice, volume 59, pages 37-46 (issn: 1995-4484, eissn: 1995-4492, Copyright policy)
  • Publisher: Mediar Press
Objective. Currently, the issues of the effect of anti-B cell therapy or inhibitor of interleukin 5 on the risk of COVID-19 infecting and outcomes in patients with ANCA-associated vasculitis (AAV) has not been completely studied. We present an analysis of the COVID-19 course and outcomes in AAV patients treated with rituximab or mepolizumab from one rheumatology center registry.Methods. From November 11 to November 15, 2020, a cross-sectional study was conducted using telephone and online surveys, and information was collected from all 128 AAV patients treated with rituximab in V.A. Nasonova Research Institute of Rheumatology. Patients mean age was 51 (20–81) ye...
Persistent Identifiers
free text keywords: Immunology, Immunology and Allergy, Rheumatology, covid-19, rituximab, mepolizumab, в-cells, interleukin-5, anca-associated vasculitis, granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, Diseases of the musculoskeletal system, RC925-935
Any information missing or wrong?Report an Issue